InspireMD Q2 2024 revenue up 5.4% to $1.74M; net loss widens; positive CGuard trial data

InspireMD, Inc.

2024-Q2 EPS reported -$0.43 revenue$3,250,000

Q2 2024 revenue $1.74M (+5.4% YoY); gross margin fell to 19.0% from 29.8% on higher costs.
Net loss $7.9M ($0.22/share) vs $5.1M ($0.24) YoY; operating expenses up 48% to $8.6M.
CGuard stent sales 2,969 units; one-year C-GUARDIANS trial primary endpoint rate 1.95% (lowest ever).
Raised $17.9M gross from full exercise of Series H warrants; cash & equivalents $47.2M at June 30.
Intends to submit PMA application to FDA this quarter; plans CGUARDIANS II TCAR trial in H2 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.